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Foster City, California.BACKGROUND Lamin A and C are nuclear ﬁlament proteins
encoded by the LMNA gene. Mutations in the LMNA gene cause
many congenital diseases known as laminopathies, including
Emery–Dreifuss muscular dystrophy, Hutchinson–Gilford progeria
syndrome, and familial dilated cardiomyopathy (DCM) with con-
duction disease. A missense mutation (N195K) in the A-type lamins
results in familial DCM and sudden arrhythmic death.
OBJECTIVE The purpose of this study was to investigate the ion
current mechanism of arrhythmia and DCM caused by the LaminA-
N195K variant.
METHODS A homozygous mouse line expressing the Lmna-N195K
mutation (LmnaN195K/N195K) that exhibited arrhythmia, DCM, and sudden
death was used. Using whole cell patch-clamp technique, we measured
action potential duration (APD), Naþ currents (INa) in ventricular
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1547-5271/$-see front matter B 2016 The Authors. Published by Elsevier Inc. on
10.1016/j.hrthm.2016.08.007RESULTS Both peak and late INa were signiﬁcantly (P o.05)
increased in LmnaN195K/N195K ventricular myocytes. Similarly,
LmnaN195K/N195K ventricular myocytes exhibited signiﬁcant
(P o.005) prolongation of APD (time to 50% [APD50] and 90%
[APD90] repolarization) and triggered activity. Acute application of
ranolazine inhibited late INa, shortened APD, and abolished
triggered activity in LmnaN195K/N195K ventricular myocytes.
CONCLUSION Inhibition of late INa may be an effective therapy in pre-
venting arrhythmia in patients with LmnaN195K mutation–related DCM.
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Lamin A/C proteins, encoded by the LMNA gene, are
intermediate ﬁlament proteins of the nuclear lamina, and
predominantly expressed in differentiated cells including
cardiomyocytes. Lamin A/C proteins are involved in chro-
matin organization, DNA repair, transcriptional regulation,
intracellular signaling pathways, and organ development.1
Mutations in the LMNA gene cause a range of congenital
diseases known as laminopathies, including Hutchison–
Gifford progeria syndrome, atypical progeroid syndrome,
Emery–Dreifuss muscular dystrophy, and limb-girdle
muscular dystrophy.2,3 A missense mutation (N195K) inthe A-type lamins results in familial dilated cardiomyopathy
with conduction system disease (DCM-CD), arrhythmias,
and sudden cardiac death. The arrhythmia in patients with
DCM carrying the LaminA-N195K variant include sinus
bradycardia, AV conduction block, and ventricular arrhyth-
mias4 and often result from ionic remodeling of atrial and
ventricular myocytes (VMs).5–7 However, the precise mech-
anisms by which the Lmna-N195K mutation in the LMNA
gene lead to ventricular arrhythmia and sudden cardiac death
remain unclear. Previously, a mouse line homozygously
expressing the Lmna-N195K variant LmnaN195K/N195K was
generated, which showed characteristics consistent with
DCM-CD and died at an early age due to arrhythmia.8 The
LmnaN195K/N195K mice developed conduction abnormalities,
which were linked to abnormal expression and distribution
of connexins (connexin40 and connexin43) in the heart and
down-regulation of the transcription factor Hf1b, which is
important in the development of the cardiac conduction
system. Using LmnaN195K/N195K mice, we tested the hypoth-
esis that alterations in VM ion channel properties maybehalf of Heart Rhythm Society. All rights reserved. http://dx.doi.org/
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LmnaN195K mutation–related DCM. We investigated
whether changes in the function of the cardiac voltage-gated
Naþ channel currents (both peak late sodium current
components) lead to changes in VM excitability and
repolarization. Ranolazine is an antianginal drug9,10 and is
known to preferentially inhibit the late Naþ channel current
(late INa)
11,12 and shorten the action potential.13 We also
tested whether inhibition of late INa by ranolazine could
correct the myocyte repolarization abnormality and the
triggered arrhythmia in VMs from LmnaN195K/N195K mice.Materials and methods
Animals
Homozygous LmnaN195K (LmnaN195K/N195K) mice were a
gift from Dr. Colin Stewart.8 Mice were a cross between
129/S1 and C57BL/6 background strains. Wild-type (WT)
and LmnaN195K mutant mice of either sex were identiﬁed
by genotyping. The study was approved in accordance with
the “Guiding Principles in the Care and Use of Animals” by
the University of Wisconsin-Madison. At 6 weeks of age,
mice were anaesthetized using isoﬂurane and weighed before
intact hearts were harvested, and the ratio of heart weight to
body weight was calculated. Live 6-week-old WT and
LmnaN195K/N195K animals were used for echocardiographic
measurements.Echocardiography
Transthoracic echocardiography was performed using a
dedicated animal Visual Sonics Vevo 770 ultrasonograph
(VisualSonics, Toronto, Canada). Anesthetized mice (1%
isoﬂurane) were maintained on a heated platform with
continuous ECG monitoring. End-diastolic and systolic left
ventricular (LV) diameter as well as anterior and posterior
wall thickness were measured online from M-mode images.
Heart rate, Doppler tracings of the LV inﬂow and outﬂow
tracts, and isovolumetric relaxation time also were analyzed.Histology
Hearts from 6-week-old LmnaN195K/N195K andWTmice were
ﬁxed in phosphate-buffered saline containing 4% parafor-
maldehyde followed by ethanol (70%) ﬁxation, embedded in
parafﬁn. Sections (5–8 µm) were stained with hematoxylin
and eosin and imaged using an inverted Nikon microscope.Transmission electron microscopy
WT and mutant mouse hearts were ﬁxed (2.5% glutaralde-
hyde, 2.0% paraformaldehyde in 0.1 mol/L cacodylate
buffer), post-ﬁxed in 1% osmium tetroxide, and embedded
in Epon 812 substitute. Samples were sliced into 70-nm
sections, post-stained in 8% uranyl acetate, and viewed on a
Philips CM120 transmission electron microscope with a
MegaView III digital camera.Electrophysiology
VMs were isolated enzymatically (Liberase Blendzyme-3 0.1
mg/mL, Roche Diagnostics Indianapolis, IN, USA) from
LmnaN195K/N195K and WT hearts as we described previously.14
Isolated rod-shaped VMs were stored in Tyrode buffer
containing 1 mmol/L Ca2þ and used for electrophysiology
within 4–6 hours of isolation. Electrophysiologic experiments
were carried out by whole cell patch-clamp technique using an
Axopatch 200B ampliﬁer (Axon Instruments, Foster City, CA)
with pCLAMP 10.2 software. Recordings were made from
healthy VMs at room temperature (unless otherwise stated)
using patch pipettes with resistance of 1.5–2.5 MΩ. Current
traces were corrected for linear capacitance and leak using-P/4
subtraction, and data were ﬁltered at 5 kHz. All solutions and
buffers are indicated in mmol/L. The extracellular solution for
recording peak INa contained the following: 5 NaCl, 90 CsCl, 1
CaCl2, 1.2 MgCl2, 11 glucose, 10 TEA-Cl, 5 and HEPES and
contained 20 µmol/L nitrendipine and 200 µmol/L Ni2þ.
Extracellular buffer for late INa contained the following: 137
NaCl, 5.4 KCl, 1.8 CaCl2, 1.2 MgCl2, 0.6 NaH2PO4, 5.5
glucose, and 5 HEPES. The intracellular buffer to measure
peak and late INa contained the following: 120 CsF, 20 CsCl, 5
NaCl, 20 EGTA, 10 TEA-CL, 1 NaATP, and 5 HEPES. Late
INa was calculated as integrated current between 50 and 750 ms
of depolarizing pulse, which was normalized to cell capaci-
tance. The bath solution for L-type Ca2þ currents contained the
following: 140 TEA-Cl, 1 MgCl2, 1.8 CaCl2, 10 glucose, and
10 HEPES (pH 7.4). The pipette solution contained the
following: 114 CsCl, 10 EGTA, 10 HEPES, and 5 MgATP
(pH ¼ 7.2) adjusted with CsOH. Action potentials (APs) were
measured at 35° ± 2oC by pacing the VMs at 5 Hz in current-
clamp mode until the action potentials reached a steady state
and then perfused with drugs. To evoke early afterdepolariza-
tions (EADs) and delayed afterdepolarizations (DADs) in the
VMs, APs were stimulated by injecting currents at 0.5 Hz. The
extracellular solution for recording AP contained the following
(in mmol/L): 137 NaCl, 5.4 KCl, 1.8 CaCl2, 1.2 MgCl2, 0.6
NaH2PO4, 5.5 glucose, and 5 HEPES. Pipette solution
contained the following (in mmol/L): 137 KCl, 1 MgCl2, 10
HEPES, 4 MgATP, 1 LiGTP, and 10 EGTA. A liquid junction
potential of about 5 mV that was noted in our AP recordings
were not corrected. Data were analyzed using Microcal Origin
software (Origin Lab Corp, Northampton, MA).
Statistical analysis
Data are given as mean± SEM. The Student t test was applied,
and P o.05 was considered signiﬁcant. More than 2 groups
were compared by analysis of variance (ANOVA) tests
followed by post hoc analysis with Tukey and Bonferroni
tests. Differences with Po.05 were considered signiﬁcant.
Results
LmnaN195K/N195K mice develop DCM with alteration
in sarcolemma and nuclear membranes
We conﬁrmed the previously reported ﬁndings in the
homozygous LMNA mutation N195K (LmnaN195K/N195K)8
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survival curves (Figure 1A), the LmnaN195K/N195K mice died
at 6–7 weeks of age, whereas WTmice remained alive. DCM
phenotype was conﬁrmed by hematoxylin and eosin staining
on sections of hearts prepared from 6-week-old WT and
mutant mice. The hearts from LmnaN195K/N195K mice had
marked enlargement of ventricular chambers and thinned
ventricular walls compared to WT (Figure 1B). Cardiac
function was measured using echocardiography. Represen-
tative M-mode echocardiograms showed LV chamber dila-
tion and thin LV walls of the LmnaN195K/N195K mice
compared to age-matched control WT mice (Figure 1C).
Functional echocardiographic analysis (summarized in
Table 1) revealed that LmnaN195K/N195K mice displayed
substantial LV chamber dilation at the end of systole and
diastole, along with a 27% increase in ratio of LV mass to
body weight. At 6 weeks of age, the LmnaN195K/N195K mice
had signiﬁcant reductions (P o.05) in ejection fraction and
fractional shortening relative to age-matched WT control
mice (Table 1). Isovolumic relaxation time increased sig-
niﬁcantly from 15.5 ± 0.07 ms to 21.2 ± 1.7 ms (P o.05),
whereas heart rate decreased signiﬁcantly in LmnaN195K/
N195K mice compared to WT. Nuclear and sarcolemmal
architecture was examined by performing transmission2 mm 2 mm
LmnaN195K/N195K
A C
B
D
Long rank test (P=0.0001)
WT
LmnaN195K/N195K
WT
Figure 1 Dilated cardiomyopathy phenotype and characteristics of LmnaN195K/N
type (WT; n ¼ 18) mice. B: Heart sections from LmnaN195K/N195K mice showing d
stain). C: Representative M-mode echocardiographic images from LmnaN195K/N195K
showing nuclear membrane blebbing (b, indicated by arrow) and alteration in s
respectively).electron microscopy on the ventricular tissue sections.
Representative transmission electron microscopic images
show an elongated nucleus with blebbing in the nuclear
membrane in the mutant myocytes (Figure 1D, b), whereas
the nuclear membrane from WT hearts showed normal
membrane structure (Figure 1D, a). The sarcolemmal
membranes of the mutant myocyte showed altered structure
(Figure 1D, d), with ridges present at every Z-line compared
to WT cells (Figure 1D, c).Prolonged action potential duration in VMs from
LmnaN195K/N195K mice
Detection of ventricular arrhythmia by in vivo radio tele-
metry was not possible because of the small size of the
LmnaN195K/N195K mice. Therefore, transmembrane AP wave-
forms were recorded from freshly isolated VMs of 6-week-
oldWT and LmnaN195K/N195Kmice. Representative AP traces
are shown in Figure 2A. Resting membrane potential
(Figure 2B) and amplitude of the AP (Figure 2B) were not
signiﬁcantly different in VMs from LmnaN195K/N195K (–65.5
± 1.5 mV) and WT (–70.2 ± 2.2 mV). Action potential
duration (APD) measured at 20% repolarization (APD20)
was not signiﬁcantly different between mutant and WT cellsLmnaN195K/N195KWT
c d
ba
195K mice. A: Kaplan–Meier analysis of LmnaN195K/N195K (n¼ 18) and wild-
ilated ventricle compared to WT heart (n ¼ 3 each) (hematoxylin and eosin
and WT mice. D: Representative transmission electron microscopic images
arcolemma membrane of LmnaN195K/N195K (d) compared to WT (a and c,
Table 1 Echocardiographic ﬁndings of 6-week-old wild-type and
LmnaN195K/N195K mice
Wild type
(n ¼ 12)
LmnaN195K/N195K
(n ¼ 11)
BW (g) 19.1 ± 0.6 9.47 ± 0.2*
LVDD (mm) 3.54 ± 0.1 3.35 ± 0.1
LVPWD (mm) 0.74 ± 0.04 0.56 ± 0.02*
LV mass (mg) 88.7 ± 4.1 54.9 ± 4.8*
LVDD/BW (mm/g) 0.18 ± 0.01 0.36 ± 0.01*
LV mass/BW (mg/g) 4.64 ± 0.18 5.90 ± 0.47*
Ejection fraction (%) 61.4 ± 2.2 43.7 ± 2.3*
Fractional shortening (%) 32.5 ± 1.5 21.0 ± 1.2*
Heart rate (bpm) 483 ± 15 405 ± 24*
Peak AO velocity (mm/s) 1433 ± 124 1151 ± 90
Isovolumic relaxation time (ms) 15.5 ± 0.7 21.2 ± 1.7*
Values are given as mean ± SEM.
BW ¼ body weight; LV ¼ left ventricular; LVDD ¼ left ventricular end-
diastolic diameter; LVPWD = left ventricular posterior wall (diastole).
*P o.05 vs wild-type mice.
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50% repolarization (APD50) and 90% repolarization
(APD90) were signiﬁcantly prolonged in Lmna
N195K/N195K
VMs compared to WT (APD50: 29.8 ± 7.9 ms vs 4.8 ± 0.7
ms, respectively; APD90: 64.1 ± 8.4 ms vs 26.5 ± 3 ms
respectively; Figure 2B).A B
C
E
Figure 2 Action potential duration (APD) prolongation and triggered activity in
AP traces in VMs from LmnaN195K/N195K and wild-type (WT) mice, stimulated at
N195K (n¼ 10) and WT (n¼ 7) from 3 animals each. *Po.05. C: Representative A
mice. Delayed afterdepolarizations indicated by arrows observed in 10 of 22 cells f
triggered early afterdepolarizations (EADs) in VMs from LmnaN195K/N195K mice mAPD prolongation associated with afterpotentials such as
EAD or DAD could trigger arrhythmia. To elicit EADs and
DADs, myocytes were stimulated at a rate of 0.5 Hz. As
shown in representative AP traces (Figures 2C–F), VMs
from LmnaN195K/N195K mice (10/23 cells from 6 animals)
showed EADs and DADs, compared to VMs from WT mice
(6 cells from 2 animals), which did not show EADs and
DADs.Peak and late sodium current are signiﬁcantly
increased in VMs from LmnaN195K/N195K mice
Prolongation of APD could be due to either the increase in
inward currents, a decrease in outward currents, or both.
Speciﬁcally, late INa has been shown to be enhanced in
acquired heart diseases and in congenital conditions such as
inherited arrhythmia and DCM15–17 and has been suggested
to play a principal role in APD prolongation. Therefore, in
the current study we focused on measuring the inward peak
and late INa in VMs from WT and Lmna
N195K/N195K mice.
Representative late INa traces measured in VMs from WT
and LmnaN195K/N195K mice are shown in Figure 3A. Late INa
was signiﬁcantly enhanced (P o.05) in LmnaN195K/N195K
VMs (–1612.8 ± 148.5 A.ms/F-1 vs –220.9 ± 66.8 A.ms/F-1D
F
ventricular myocytes (VMs) from LmnaN195K/N195K mice. A: Representative
5 Hz at 37°C. B: Mean action APD20, APD50, and APD90 from Lmna
N195K/
P traces in VMs stimulated at 0.5 Hz at 37°C fromWT and LmnaN195K/N195K
rom 6 animals with LmnaN195K mutation. E: Representative spontaneously
easured at 37°C. F: Expanded single AP showing EAD.
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Figure 3 Increased peak and late INa in ventricular myocytes (VMs) in Lmna
N195K/N195K mice. A: Representative traces of INaL in VMs from wild-type (WT) and
LmnaN195K/N195K mice. Protocol shown in inset (holding potential of -120 mV step to 60 mV with 10 mV step pulse). B: Mean integrals of INa,L, normalized to cell
capacitance from WT (n ¼ 6) and LmnaN195K/N195K (n ¼ 11) from 3 animals each. C: Representative traces of peak INa from WT and LmnaN195K/N195K VMs. Protocol
shown in inset.D:Mean current–voltage relationship for peak INa in Lmna
N195K/N195Kmyocytes (n=9) andWT (n=11). # &*Po.05 from 3 and 4 animals, respectively.
Heart Rhythm, Vol 13, No 11, November 20162232in WT cells; Figure 3B). The magnitude of peak INa in
LmnaN195K/N195K VMs was signiﬁcantly greater (P o.05)
compared to WT (–34.25 ± 4.4 pA/pF vs –21.36 ± 1.8 pA/
pF; Figures 3C and D).
Ranolazine inhibits late INa in VMs isolated from
LmnaN195K/N195K mice
We determined the effect of ranolazine (5 or 10 µM) on the of
late INa of VMs from Lmna
N195K/N195K mice. Ranolazine (10
µM) caused complete inhibition of late INa in Lmna
N195K/
N195KVMs (Figures 4A and B). In addition, perfusion of cells
with 2 µM tetrodotoxin (TTX) also signiﬁcantly inhibited the
INa,L of VMs from Lmna
N195K/N195K mice (ANOVA Po.05,
post hoc analysis by Tukey and Bonferroni tests; Figures 4A
and B), which conﬁrmed that the late INa observed in the VMs
from LmnaN195K/N195Kmice was indeed Naþ current. We also
investigated the effect of ranolazine in the L-type Ca2þ
currents (ICa,L) in the VMs. ICa,L density was not signiﬁcantly
different in the VMs from LmnaN195K/N195K mice relative to
WT mice (Figure 5). Perfusion of cells with ranolazine (10
µM) had no effect on peak ICa,L in the VMs from WT or
LmnaN195K/N195K mice (Figure 5).
Ranolazine shortens prolonged APD of VMs from
LmnaN195K/N195K mice
We then determined the effect of ranolazine on APD of VMs
from LmnaN195K/N195K mice. As shown in Figures 6A and B,ranolazine (10 µM) signiﬁcantly shortened APD50 and APD90
(ANOVA Po.05, post hoc analysis by Tukey and Bonferroni
tests). We also studied the effect of the sodium channel
inhibitor TTX on APD in the VMs from LmnaN195K/N195K
mice. When the APs reached a steady state, the myocytes were
superfused with 2 µM TTX, which signiﬁcantly shortened the
prolonged APD50 and APD90 (P ¼ .04; Figure 6C). The
resting membrane potential and the amplitude of the AP were
not signiﬁcantly different between WT and LmnaN195K/N195K
myocytes or with TTX and ranolazine treatment in
LmnaN195K/N195K myocytes (summarized in Table 2).Ranolazine abolishes EADs and DADs and suppresses
triggered activity in VMs from LmnaN195K/N195K mice
Previous studies have demonstrated that ranolazine short-
ens APD, reduces APD variability, and suppresses trig-
gered activity in VMs in several experimental models of
arrhythmias in which late INa was enhanced.
13,18–21 There-
fore, the effect on ranolazine on spontaneous EADs and
DADs in VMs from LmnaN195K/N195K mice was deter-
mined. Ranolazine perfusion completely abolished EADs,
DADs, and DAD-induced triggered activity (Figure 6B) in
LmnaN195K/N195K myocytes. These data suggest that by
reducing the magnitude of the enhanced INa,L, ranolazine
reduces the prolongation of APD, abolishes DADs,
and suppresses triggered activity in the VMs from
LmnaN195K/N195K mice.
AB
Figure 4 Ranolazine (Ran) and tetrodotoxin (TTX) inhibits INaL Lmna
N195K/N195K ventricular myocytes. A: Representative traces of INaL from Lmna
N195K/
N195K alone and in presence of Ran (10 µM) and TTX (2 µM). Voltage protocol shown in inset. B:Mean integrals of INa,L normalized to myocyte capacitance in
LmnaN195K/N195K (n ¼ 15) or in presence of ran (n ¼ 8) or TTX (n ¼ 6) from 5 animals. *P o.05.
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The cardiac phenotype of laminopathies resulting from
mutations in the LMNA gene include atrial ﬁbrillation,
ventricular arrhythmia, conduction abnormalities, andFigure 5 Effect of ranolazine (Ran) on ICa,L density in ventricular myocytes. A
myocytes in presence and absence of 10 µM Ran at -50, -20,0,20 mV test potenti
potential of 60 mV with 10mV step potential. C, D: Current–voltage relationship a
( n ¼ 9), LmnaN195K/N195K þ Ran (n ¼ 5) from 4–5 animals.sudden cardiac death as well as DCM with congestive heart
failure.4,22–26 Ventricular arrhythmias occur commonly in
patients with LMNA mutations and sudden cardiac
death.23,26–28 Although clinical manifestations of cardiac, B: Representative ICa,L traces from wild-type (WT) and Lmna
N195K/N195K
al. Voltage protocol shown in inset with holding potential of -50 mV, peak
nd mean peak ICa,L from WT (n ¼ 10), WTþ Ran (n ¼ 4), LmnaN195K/N195K
AB
C
Figure 6 Ranolazine shortens prolongation of action potential in ventricular myocytes from LmnaN195K/N195Kmice.A:Representative traces of action potential at 5
Hz and mean APD50 and APD90 from Lmna
N195K/N195K mice (n ¼ 7) or in presence of 5 µM and 10 µM ranolazine (n ¼ 6 each). B: Representative action potential
(AP) traces at 0.5 Hz showing triggered activity in LmnaN195K/N195Kmice, which was inhibited by perfusing 10 µM ranolazine (n¼ 6).C: Representative traces of AP
at 5 Hz and mean APD50 and APD90 from Lmna
N195K/N195K VMs (n ¼ 5) and in presence of 2 µM tetrodotoxin (TTX; n ¼ 5). Increased action potential duration
(APD) was reduced in presence of TTX. APD50¼ action potential duration at 50% repolarization; APD90¼ action potential duration at 90% repolarization. *Po.05.
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reported, changes in major cardiac ion currents have not
been described. To our knowledge, this is the ﬁrst report to
describe alteration cardiac sodium channel function in VMs
in a model expressing LMNAN195K mutation. Using
LmnaN195K/N195K mice, we showed that VMs from the
mutant mice have signiﬁcantly prolonged APD, increased
incidences of EADs and DADs, and triggered activity. Both
peak and late INa were signiﬁcantly increased in Lmna
N195K/
N195K VMs. INa is responsible for the rapid depolarization or
upstroke (phase 0) of APs in cardiomyocytes. INa largelyinactivates within 1–5 ms, and approximately 1% of INa
inactivates slowly during the plateau phase of the AP.
Although the magnitude of late INa is relatively small, it
contributes signiﬁcantly to the shape of the AP as well as
the initiation and maintenance of cardiac arrhythmias.15–17
The possible causes of an increase in peak and late INa in the
VMs from LmnaN195K/N195K mice might include structural
remodeling in the VMs altering the SCN5a macromolecular
complex impacting the channel function29,30 or direct alter-
ations of SCN5a gene expression as a consequence of altered
expression of the lamin A/C protein due to haploinsufﬁciency
Table 2 Summary of action potentials stimulated at rate of 5 Hz at 37°C
Resting membrane
potential (mV) Overshoot (mV) Amplitude (mV) APD50 (ms) APD90 (ms)
Wild type (n ¼ 10) –74.3 ± 2 38.7 ± 4 112.9 ± 4 4.8 ± 1 26.5 ± 3
LmnaN195K/N195K (n ¼ 10) –69.5 ± 2 42.2 ± 4 111.7 ± 5 29.8 ± 8* 64.1 ± 8*
LmnaN195K/N195K (n ¼ 6) –66.6 ± 5 22.9 ± 3 89.5 ± 3 34.8 ± 7 83.7 ± 8
LmnaN195K/N195K þ 5 µM Ran (n ¼ 6) –70.0 ± 1 26.5 ± 5 96.5 ± 5 25.1 ± 4 70.0 ± 6
LmnaN195K/N195K þ 10 µM Ran (n ¼ 6) –71.4 ± 2* 26.3 ± 4 97.7 ± 5 12.1 ± 4* 40.2 ± 8*
LmnaN195K/N195K (n ¼ 6) –67.2 ± 2 28.4 ± 5 95.5 ± 5 31.8 ± 9 95.5 ± 14
LmnaN195K/N195K þ 2 µM tetrodotoxin (n ¼ 5) –65.8 ± 2 28.7 ± 4 105.8 ± 2 11.8 ± 1* 42.7 ± 7*
Data are given as mean ± SEM.
APD50 ¼ action potential duration at 50% repolarization; APD90 ¼ action potential duration at 90% repolarization; n ¼ number of cells; Ran ¼ ranolazine.
*P o.05.
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However, the precise role of the nuclear localized lamin A/
C proteins regulating ion channel function is not well
understood. Recent reports, albeit preliminary in nature,
demonstrated that 2 lamin A/C mutations, V445E (associated
with LV noncompaction disease)31 and R545H (associated
with cardiac conduction disease),32,33 affected SCN5a
expression and sodium channel function. Co-expression of
these LMNA mutations with SCN5a in HEK293 cells caused
a reduction in peak INa density compared to co-expression
with WT LMNA. The latter report also suggested that the
apparent reduction in INa is dependent on constitutive
phosphorylation of lamin at serine 22, which is sufﬁcient to
partially rescue peak INa in R545H mutant lamin.
32 The
increase in peak INa in Lmna
N195K/N195K myocytes could be
secondary effects to DCM in the mice.
We also showed in this study that an increased INa,L is
associated with occurrences of EADs and DADs in
LmnaN195K/N195K myocytes. The underlying mechanism
likely is an enhancement of the INa,L leading to an increase
in intracellular Naþ. This causes a net increase in Ca2þ via
the sarcolemmal sodium/calcium exchanger during diastole
and results in a depolarizing membrane current inducing
increased automaticity, EADs, and DADs, thereby facilitat-
ing arrhythmogenesis.16,17,34 Although ICa,L was unchanged,
it may be possible that changes in the function of transient
outward potassium current (Ito) contribute to prolongation of
APD. Future investigations should reveal the relative con-
tribution of Ito along with late INa to the pathogenesis of
arrhythmia in this disease model. Nevertheless, we showed
that the inhibitor of late INa ranolazine and low concen-
trations of the INa blocker TTX signiﬁcantly reduced the
magnitude of late INa and reversed prolongation of APD in
myocytes from LmnaN195K/N195K mice. Furthermore, ranola-
zine abolished EADs and DADs. Ranolazine has been shown
to shorten APD, reduce APD variability, and suppress
triggered activity in VMs in various experimental models
of arrhythmia and DCM.18–21 In addition, ranolazine has
been shown to suppress cardiac arrhythmias.35Conclusion
The results of our studies clearly show that inhibition of late
INa with ranolazine shortened the prolonged APD andsuppressed trigged activity in VMs of LmnaN195K/N195K
mice, thus suggesting that inhibition of late INa could be
useful for managing ventricular arrhythmias in patients with
LmnaN195K mutation–related DCM-CD.References
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